Pallas Capital Advisors LLC Takes Position in Grail, Inc. (NASDAQ:GRAL)

Pallas Capital Advisors LLC bought a new stake in Grail, Inc. (NASDAQ:GRAL - Free Report) during the first quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund bought 10,048 shares of the company's stock, valued at approximately $257,000.

A number of other institutional investors have also modified their holdings of GRAL. Crcm LP acquired a new position in shares of Grail in the fourth quarter valued at approximately $65,061,000. Sessa Capital IM L.P. acquired a new position in shares of Grail in the fourth quarter valued at approximately $53,550,000. Primecap Management Co. CA acquired a new position in shares of Grail in the fourth quarter valued at approximately $37,118,000. Baker BROS. Advisors LP purchased a new stake in shares of Grail in the fourth quarter valued at approximately $29,098,000. Finally, Vanguard Group Inc. purchased a new stake in shares of Grail in the fourth quarter valued at approximately $25,902,000.

Grail Price Performance

Grail stock opened at $41.31 on Friday. Grail, Inc. has a 1-year low of $12.33 and a 1-year high of $63.99. The company has a market cap of $1.49 billion and a PE ratio of -0.68. The stock's 50 day moving average price is $35.06 and its 200 day moving average price is $30.00.

Grail (NASDAQ:GRAL - Get Free Report) last posted its quarterly earnings results on Tuesday, May 13th. The company reported ($3.10) earnings per share for the quarter, beating analysts' consensus estimates of ($4.03) by $0.93. The business had revenue of $31.84 million during the quarter, compared to analysts' expectations of $35.80 million. On average, equities research analysts anticipate that Grail, Inc. will post -15.15 EPS for the current fiscal year.

Analysts Set New Price Targets

A number of analysts recently weighed in on the company. Morgan Stanley lifted their price target on Grail from $16.00 to $20.00 and gave the company an "equal weight" rating in a research note on Tuesday, March 18th. Canaccord Genuity Group lifted their price target on Grail from $32.00 to $43.00 and gave the company a "buy" rating in a research note on Wednesday, May 14th.

Insiders Place Their Bets

In other Grail news, CEO Robert P. Ragusa sold 94,035 shares of the business's stock in a transaction on Friday, May 2nd. The stock was sold at an average price of $33.93, for a total transaction of $3,190,607.55. Following the sale, the chief executive officer now directly owns 734,627 shares in the company, valued at approximately $24,925,894.11. The trade was a 11.35% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, President Joshua J. Ofman sold 48,213 shares of the business's stock in a transaction on Friday, May 2nd. The stock was sold at an average price of $33.93, for a total value of $1,635,867.09. Following the sale, the president now owns 511,460 shares in the company, valued at approximately $17,353,837.80. The trade was a 8.61% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 183,398 shares of company stock worth $6,222,694. 1.85% of the stock is owned by corporate insiders.

About Grail

GRAIL, Inc operates as a commercial-stage healthcare company, which engages in the development of a technology for early detection of cancer. It utilizes machine learning, software, and automation to detect and identify multiple deadly cancer types in earlier stages. The company was founded by Jeffrey T.

Want to see what other hedge funds are holding GRAL? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Grail, Inc. (NASDAQ:GRAL - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.